Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA

Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426–37.

Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.

Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family-balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76:25–37.

Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 2000;275:10308–14.

Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009;360:2438–44.

Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.

Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis. 2002;61:960–7.

Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47–52.

Novartis Pharmaceuticals Corporation. Prescribing information for ILARIS (canakinumab). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf . Accessed on 31 Aug 2018.

Hong DS, Janku F, Naing A, et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investig New Drugs. 2015;33:621–31.

Colquhoun HL, Levac D, O’Brien KK, et al. Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol. 2014;67:1291–4.

Al-Almaie SM, Al-Baghli NA. Evidence based medicine: an overview. J Fam Community Med. 2003;10:17–24.

Gómez-García F, Ruano J, Gay-Mimbrera J, et al. A scoping review protocol to explore the use of interleukin-1-targeting drugs for the treatment of dermatological diseases: indications, mechanism of action, efficacy, and safety. Dermatol Ther (Heidelb). 2018;8:195–202.

Aromataris E, Munn Z (Editors). Joanna Briggs Institute reviewer’s manual. The Joanna Briggs Institute, 2017. Available from https://reviewersmanual.joannabriggs.org/ . Accessed 18 Aug 2018.

Tricco AC, Lillie E, Zarin W, O’Brien KK, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018. https://doi.org/10.7326/m18-0850 (Epub ahead of print).

Carapito R, Isidor B, Guerouaz N, et al. Homozygous IL36RN mutation and NSD1 duplication in a patient with severe pustular psoriasis and DITRA-unrelated symptoms. Br J Dermatol. 2015;172:302–5.

Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017. https://doi.org/10.1172/jci.insight.94838 .

Zimmer C, Moll M, Rieber N, Goldbach-Mansky R, Aksentijevich I, Kuemmerle-Deschner J. IL-1 inhibition in a patient with polymorphism in the interleukin 1-receptor type 1 gene and clinical phenotype of CRMO/DIRA. Ann Rheum Dis. 2013;71(SUPPL. 3):257.

Cuperus W, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T > C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin. JAAD Case Rep. 2018;4(2):192–5.

Capusan TM, et al. Combined therapy in 2 cases of pustular generalized psoriasis with IL36RN gene mutations. Pediatric Dermatol. 2017;34(Supplement 2):S46.

Cordoro KM, Ucmak D, Hitraya-Low M, Rosenblum MD, Liao W. Response to interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA). JAMA Dermatol. 2017;153:106–8.

Caorsi R, Minoia F, Viglizzo G, et al. The therapeutic challenge of DITRA syndrome. Pediatr Rheumatol. 2017;15(Supplement):1.

Glerup M, Veirum J, Iversen L, Christiansen M, Herlin T. Generalized pustular psoriasis in infant with heterozygous mutation in the IL36RN gene successfully treated with infliximab. Pediatr Rheumatol Online J. 2014;12(Suppl 1):P79.

Mendonca LO, Malle L, Donovan FX, et al. Deficiency of interleukin-1 receptor antagonist (DIRA): report of the first Indian patient and a novel deletion affecting IL1RN. J Clin Immunol. 2017;37:445–51.

Panju AH, Bell CM. Policy alternatives for treatments for rare diseases. CMAJ. 2010;182(17):E787–92.

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2:38–43.

https://www.ncbi.nlm.nih.gov/clinvar?term=147679[MIM] . Accessed 12 Sep 2018.

https://www.ncbi.nlm.nih.gov/clinvar?term=605507[MIM] . Accessed 12 Sep 2018.

Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol. 2012;148:747–52.

Schnellbacher C, Ciocca G, Menendez R, et al. Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr Dermatol. 2013;30:758–60.

Mendoní ALO, et al. A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of IL1RA (DIRA). J Clin Immunol. 2017;37(Supplement 1):S19.

Berdeli A, Sözeri B, Gerceker Türk B, Oz A, Mir S. Turkish DIRA patient with novel IL1RN gene mutation. Pediatr Rheumatol. 2015;13(Suppl 1):P181.

Ulusoy E, Karaca NE, El-Shanti H, Kilicoglu E, Aksu G, Kutukculer N. Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report. J Med Case Rep. 2015;9:145.

Thacker PG, Binkovitz LA, Thomas KB. Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory condition that mimics multiple classic radiographic findings. Pediatr Radiol. 2012;42:495–8.

Jesus AA, Osman M, Silva CA, et al. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum. 2011;63:4007–17.

Stenerson M, Dufendach K, Aksentijevich I, Brady J, Austin J, Reed AM. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum. 2011;63:4018–22.

Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–4.

Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis—a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27:1067–77.

Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2017;140:1545–7.

Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases: an emerging concept encompassing various inflammatory keratinization disorders of the skin. J Dermatol Sci. 2018;90:105–11.